RBM15
Summary: Members of the SPEN (Split-end) family of proteins, including RBM15, have repressor function in several signaling pathways and may bind to RNA through interaction with spliceosome components (Hiriart et al., 2005 [PubMed 16129689]).[supplied by OMIM, Feb 2009].
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
RNA binding motif protein 15 | MIM:606077 | Ensembl:ENSG00000162775 | HGNC:HGNC:14959 | PA34264 | 1p13.3 |
GO terms in RBM15
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
CC | IBA | GO:0005634 | nucleus |
CC | IDA | GO:0005654 | nucleoplasm |
CC | IDA | GO:0016607 | nuclear speck |
CC | IEA | GO:0031965 | nuclear membrane |
CC | IDA | GO:0036396 | RNA N6-methyladenosine methyltransferase complex |
BP | IDA | GO:0000381 | regulation of alternative mRNA splicing, via spliceosome |
BP | IBA | GO:0000398 | mRNA splicing, via spliceosome |
BP | IDA | GO:0001510 | RNA methylation |
BP | IEA | GO:0001569 | branching involved in blood vessel morphogenesis |
BP | IEA | GO:0007221 | positive regulation of transcription of Notch receptor target |
BP | IDA | GO:0009048 | dosage compensation by inactivation of X chromosome |
BP | IEA | GO:0016032 | viral process |
BP | ISS | GO:0038163 | thrombopoietin-mediated signaling pathway |
BP | IEA | GO:0045638 | negative regulation of myeloid cell differentiation |
BP | IDA | GO:0045652 | regulation of megakaryocyte differentiation |
BP | IDA | GO:0045892 | negative regulation of transcription, DNA-templated |
BP | IEA | GO:0048536 | spleen development |
BP | IEA | GO:0060412 | ventricular septum morphogenesis |
BP | IEA | GO:0060674 | placenta blood vessel development |
MF | IBA | GO:0003676 | nucleic acid binding |
MF | HDA | GO:0003723 | RNA binding |
MF | IDA | GO:0003723 | RNA binding |
MF | IDA | GO:0003729 | mRNA binding |
MF | IPI | GO:0005515 | protein binding |
Gene expression in normal tissue: RBM15
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in RBM15
Database | Pathway ID | Pathway Des. |
---|
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD286 | Nsc 632839 | 4 |
iGMDRD871 | BRD6368 | 2 |
iGMDRD366 | PI-103 | 2 |
iGMDRD505 | Pevonedistat | 1 |
iGMDRD246 | NPC26 | 2 |
iGMDRD42 | Vorinostat | 1 |
iGMDRD353 | PD0325901 | 1 |
iGMDRD322 | FK 866 | 2 |
iGMDRD990 | PL.DI | 1 |
iGMDRD121 | GMX1778 | 3 |
iGMDRD208 | Necrosulfonamide | 1 |
iGMDRD137 | Indisulam | 3 |
iGMDRD289 | Parthenolide | 2 |
iGMDRD864 | BRD-K99006945 | 1 |
iGMDRD705 | Nakiterpiosin | 5 |
iGMDRD267 | Oligomycin A | 6 |
iGMDRD57 | Chloropentafluorobenzene | 4 |
iGMDRD314 | Tanespimycin | 3 |
iGMDRD351 | GW843682X | 6 |
iGMDRD123 | Isoevodiamine | 4 |
iGMDRD176 | Decitabine | 1 |
iGMDRD84 | Lovastatin acid | 3 |
iGMDRD486 | Tosedostat | 3 |
iGMDRD584 | VER 155008 | 2 |
iGMDRD560 | MK-2206 | 2 |
iGMDRD681 | SB-743921 | 1 |
iGMDRD50 | Cytarabine | 1 |
iGMDRD79 | Gemcitabine | 2 |
iGMDRD188 | Piperlongumine | 5 |
iGMDRD100 | Zebularine | 4 |
iGMDRD730 | Kahalalide F | 2 |
iGMDRD74 | Idarubicin | 1 |
iGMDRD399 | Selumetinib | 3 |
iGMDRD851 | BRD-K34222889 | 1 |
iGMDRD562 | Navitoclax | 2 |
iGMDRD398 | Sepantronium | 4 |
iGMDRD60 | Quinoclamine | 2 |
iGMDRD64 | Parbendazole | 4 |
iGMDRD356 | PNU-74654 | 3 |
iGMDRD451 | Serdemetan | 1 |
iGMDRD138 | PX 12 | 4 |
iGMDRD852 | BRD-K35604418 | 1 |
iGMDRD255 | SB225002 | 2 |
iGMDRD260 | FQI-2 | 4 |
iGMDRD171 | Pemetrexed | 3 |
iGMDRD117 | Docetaxel | 1 |
iGMDRD294 | Batimastat | 1 |
iGMDRD446 | LY 2183240 | 1 |
iGMDRD193 | Fqi1 | 3 |
iGMDRD152 | 179324-69-7 | 7 |
iGMDRD61 | Kinetin riboside | 2 |
iGMDRD280 | CYTOCHALASIN B | 2 |
iGMDRD466 | Chaetocin | 6 |
iGMDRD126 | Tipifarnib | 9 |
iGMDRD151 | CHM-1 | 6 |
iGMDRD554 | CHEMBL1434137 | 2 |
iGMDRD599 | Salermide | 1 |
iGMDRD1008 | SR-II-138A | 1 |
iGMDRD779 | PRL-3 Inhibitor I | 2 |
iGMDRD483 | SCH-529074 | 3 |
iGMDRD494 | Neopeltolide | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in RBM15